載入...
Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥65 Years With Nonvalvular Atrial Fibrillation
Dabigatran has been shown to be superior to warfarin for stroke prevention in nonvalvular atrial fibrillation (NVAF) but with higher out-of-pocket costs for patients. Although dabigatran has been shown to be cost effective from a societal perspective, cost implications for individual patients and in...
Na minha lista:
| 發表在: | Am J Cardiol |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4780215/ https://ncbi.nlm.nih.gov/pubmed/26552509 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.amjcard.2015.09.048 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|